ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
October 15, 2024 07:50 ET
|
ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
October 07, 2024 07:55 ET
|
ZyVersa Therapeutics
ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 15:45 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
October 01, 2024 07:00 ET
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence
September 30, 2024 22:00 ET
|
LeaderMed Group; Combiphar
LeaderMed and Combiphar form a joint venture to tackle Indonesia’s diabetes and obesity crisis with LM-008 and UltraSculpt, launching a Phase 3 trial.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
Fractyl Health to Participate in Upcoming September Investor Conferences
September 03, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
August 21, 2024 14:16 ET
|
ProLynx Inc.
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx...
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 14, 2024 16:05 ET
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates